0001610618-24-000016.txt : 20240312
0001610618-24-000016.hdr.sgml : 20240312
20240312214808
ACCESSION NUMBER: 0001610618-24-000016
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240311
FILED AS OF DATE: 20240312
DATE AS OF CHANGE: 20240312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tari Leslie
CENTRAL INDEX KEY: 0001870270
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36912
FILM NUMBER: 24744446
MAIL ADDRESS:
STREET 1: C/O CIDARA THERAPEUTICS, INC.
STREET 2: 6310 NANCY RIDGE DR SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cidara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001610618
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461537286
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-752-6170
MAIL ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: K2 THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20140611
4
1
wk-form4_1710294467.xml
FORM 4
X0508
4
2024-03-11
0
0001610618
Cidara Therapeutics, Inc.
CDTX
0001870270
Tari Leslie
6310 NANCY RIDGE DRIVE
SUITE 101
SAN DIEGO
CA
92121
0
1
0
0
CHIEF SCIENTIFIC OFFICER
0
Common Stock
2024-03-11
4
S
0
21029
0.6698
D
258681
D
Common Stock
1484
I
By spouse
The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on November 20, 2023.
/s/ Shane Ward, Attorney-in-Fact
2024-03-12